Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-26
2006-09-26
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S085100, C424S085200
Reexamination Certificate
active
07112409
ABSTRACT:
The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
REFERENCES:
patent: 5223395 (1993-06-01), Gero
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5554512 (1996-09-01), Lyman et al.
patent: 5772998 (1998-06-01), Dasch et al.
patent: 288088 (1988-04-01), None
patent: WO93/06489 (1993-04-01), None
patent: WO94/26891 (1994-11-01), None
patent: WO96/400098 (1996-12-01), None
patent: WO97/06251 (1997-02-01), None
T. Sado et al., “Immediate and long-term effects of radiation on the immune system of specific-pathogen-free mice”, Int. J. Radiat. Biol., 1988, vol. 53, No. 1, pp. 177-187.
S.A. Lorimore et al., “Late effects of X-irradiation on haemopoietic stem cells in CBA/H mice”, Int. J. Radiat. Biol., 1990, vol. 57, No. 2, pp. 385-393.
B.I. Lord et al., “Long term effects of plutonium-239 and radium-224 on the distribution and performance of pluripotent haemopoietic progenitor cells and their regulatory microenviornment”, Int. J. Radiat. Biol., 1991, vol. 59, No. 1, pp. 211-227.
T. Grande et al., “Residual haematopoietic damage in adult and 8 day-old mice exposed to 7 Gy of X-rays”, Int. J. Radiat. Biol., 1993, vol. 63, No. 1, pp. 59-67.
M. Tavassoli et al., “Radiosensitivity of Stromal Cells Responsible for In Vitro Maintenance of Hemopoietic Stem Cells in Continuous, Long-term Marrow Culture”, Exp. Hematol, May 1982, vol. 10, No. 5, pp. 435-443.
T. Jones et al., “A Mathematical Model for Radiation-Induced Myelopoiesis”, Radiation Research vol. 128, 1991, pp. 258-266.
S. Cooper et al., “Myelosupressive effects in vivo with very low dosages of monomeric recombinant murine macorphage inflammatory protein-1α”, Experimental Hematology, vol. 22, 1994, pp. 186-193.
D. Dunlop et al., “Demonstration of Stem Cell Inhibition and Myeloprotective Effects of SCI/rhMIP1α In Vivo”, Blood, vol. 79, No. 9, 1992, pp. 2221-2225.
S. Jacobsen et al., “Bidirectional Effects of Transforming Growth Factor β(TGF-β)on Colony-Stimulating Factor-Induced Human Myelopoiesis In Vitro: Differential Effects of Distinct TGF-β Isoforms”, Blood, vol. 78, No. 9, 1991, pp. 2239-2247.
R. Maze et al., “Myelosuppressive Effects In Vivo Of Purified Recombinant Murine Macrophase Inflammatory Protein-1α”, Journal of Immunology, vol. 149, pp. 1004-1009.
Mayani et al., “Biology of the hemopoietic microenviornment”, Exp. Hematol, 1992, vol. 49, pp. 225-233.
S. Cannistra et al., “Regulation of the Production and Function of Granulocytes and Monocytes”, Seminars in Hematology, vol. 25, No. 3, 1988, pp. 173-188.
A.J. Becker et al., “The Effect of Differing Demands for Blood Cell Production on DNA Synthesis by Hemopoietic Colony-Forming Cells of Mice”, Blood, vol. 26, No. 3, 1965, pp. 296-308.
J. Domenech et al., “Prolonged Impairment of Hematopoiesis After High-Dose Therapy Followed by Autologous Bone Marrow Transplantation”, Blood, vol. 85, No. 11, 1995, pp. 3320-3327.
M. Cairo et al., “Circulating Granulocyte Colony-Stimulating Factor(G-CSF)Levels After Allogeneic and Autologous Bone Marrow Transplantation: Endogenous G-CSF Production Correlates With Myeloid Engraftment”, Blood, vol. 79, No. 7, 1992, pp. 1869-1873.
B. Sallerfors et al., “Granulocyte-macrophage colony-stimulating factor(GM-CSF)and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia”, British Journal of Haematology, 1991, vol. 78, pp. 343-351.
K. Brasel et al., “Hematologic Effects of flt3 Ligand In Vivo in Mice”, Blood, vol. 88, No. 6, 1996, pp. 2004-2012.
M. Lisovsky et al., “Flt3 Ligand Stimulates Proliferation and Inhibits Apoptosis of Acute Myeloid Leukemia Cells: Regulation of Bcl-2 and Bax”, Blood, vol. 88, No. 10, 1996, pp. 3987-3997.
J.E. Talmadge et al., “Rapid immunologic reconstruction following transplantation with mobilized peripheral blood stem cells as compaired to bone marrow”, Bone Marrow Transplantation, 1997, vol. 19, pp. 161-172.
C. Selig et al., “Cytokines and Progenitor Cells of Granulocytopoiesis in Peripheral Blood of Patients with Bacterial Infections”, Infection and Immunity, 1995, pp. 104-109.
G. Baiocchi et al., “Autologous Stem Cell Transplantation: Sequential Production of Hematopoietic Cytokines Underlying Granulocyte Recovery”, Cancer Research, 1996, vol. 51, pp. 1297-1303.
XP-000920913, Blumenthal R.D.: “Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy”, CANCER, vol. 88, Jan. 15, 2000, pp. 333-343.
03013864, Patent Abstracts of Japan vol. 0151, No. 31, Mar. 29, 19991 and JP 03 013864.
Stratagene catalogue 1988. p. 39.
Scadden et al. AIDS 1994, vol. 8, pp. 193-196. “In vitro effects of stem-cell factor or interleukin-3 on myelosurppresion associated with AIDS.”
Blumenthal RD, et al. Exp. Hematol. 1998, vol. 26; pp. 859-868. “Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.”
Strait RT et al., 1997, Acad. Emerg. Med. vol. 4, pp. 44-51. “A pilot study of the predictive value of plastma TNF-alpha and interleukin 1 beta forStreptococcus pneumoniae bacterimiain febrile children.”
Maxwell et al., Semin. Oncol. Nurs., 1992, vol. 8, pp. 113-123.
Blijham, Anticancer Drugs, 1993, vol. 4, pp. 527-533.
Boesen et al., Biotherapy, 1993, vol. 6, pp. 291-302.
Testa et al., Anticancer Res. 1985, vol. 5, pp. 101-110.
Meijne et al. Exp. Hematol., 1991, vol. 19, pp. 617-623.
Eaves et al., Tiss. Culture Meth., 1991, vol. 13, pp. 55-62.
McNiece et al., Blood, 1989, vol. 75, pp. 609-612.
Lowry et al. J. Cell Biochem., 1995, vol. 58, pp. 410-415.
Shpall et al., Cancer Treat. Res., 1997, vol. 77, pp. 143-157.
Selig et al., Blood, 1995, vol. 79, pp. 1869-1873.
Wagemaker et al., Stem Cells, 1995, vol. 13, pp. 165-171.
Chen et al., Jap. J. Clin. Oncol., 1996, vol. 26, pp. 18-23.
G.L. Denardo et al., “Overview of radiation myelotoxicity secondary to radioimmunotherapy using131I-Lym-1 as a model”, Cancer, 1994, vol. 73, pp. 1038-1048.
M.E. Juweid et al., “Prediction of hematologic toxicity after radioimmunotherpay with131I-labeled anticarcinoembryonic antigen monoclonal antibodies”, J. Nucl. Med., 1999, vol. 40, pp. 1609-1616.
R. D. Bluemnthal et al., “Modulation of marrow proliferation and hemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines”, Clinical Can. Res. vol. 8, 1301-1309, May 2002.
M. Lisovsky et al., “Flt3-ligand production by human bone marrow stromal cells”, Leukemia, 1996, vol. 10, pp. 1012-1018.
T. Papayannopoulou et al., “In vivo effects of flt3/flk2-ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor”, Blood, 1997, vol. 90, pp. 620-629.
Bird, Science, 1988, vol. 242, pp. 423-426.
Huston et al., Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 5879-5883.
Ward et al., Nature, 1989, vol. 334, pp. 544-546.
Cluitmans et al., Ann. Hematol, 1997, vol. 75 (1-2), pp. 27-31.
Chopra et al., J. Cancer Res. Clin. Oncol., 1997, vol. 123, pp. 167-172.
Chopra et al., Cancer J. Sci. Am. , 1996, vol. 2, pp. 279-285.
Chopra et al., Cancer Investigation, 1998, vol. 16 (3), pp. 152-159.
J. A. Siegel et al., “Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy”, Nucl Med Biol., 1989, vol. 16, pp. 553-559.
A. Loh et al, “Pharmacokinetic model of iodine-131-G
Blumenthal Rosalyn D.
Goldenberg David M.
Center for Molecular Medicine and Immunology
Faegre & Benson LLP
Mertz Prema
LandOfFree
Method of determining cytokine dosage for myelosuppressive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining cytokine dosage for myelosuppressive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining cytokine dosage for myelosuppressive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585767